NCT00123968 arm group 5f5468d54f2b86e7e60fac196581d7d0 [clinicaltrials_resource:NCT00123968/arm-group/5f5468d54f2b86e7e60fac196581d7d0]
VRC-DILUENT013-DIL-VP [clinicaltrials_resource:3e01fb987a45f25d4f3f871f81035e80]VRC-HIVADV014-00-VP [clinicaltrials_resource:dd9b5329b9e1d715f80edd2b58a61ec0]VRC-HIVDNA016-00-VP [clinicaltrials_resource:e34facc467468a4fc0078a4d435c627d]Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults [clinicaltrials:NCT00123968]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00123968 arm group 5f5468d54f2b86e7e60fac196581d7d0 [clinicaltrials_resource:NCT00123968/arm-group/5f5468d54f2b86e7e60fac196581d7d0]
Bio2RDF identifier
NCT00123968/arm-group/5f5468d54f2b86e7e60fac196581d7d0
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 5468d54f2b86e7e60fac196581d7d0
description [clinicaltrials_vocabulary:description]
Participants will receive the ...... ctored HIV vaccine at Day 168.
identifier
clinicaltrials_resource:NCT00123968/arm-group/5f5468d54f2b86e7e60fac196581d7d0
title
NCT00123968 arm group 5f5468d54f2b86e7e60fac196581d7d0
@en
type
label
NCT00123968 arm group 5f5468d5 ...... 468d54f2b86e7e60fac196581d7d0]
@en